Reports Q3 revenue $126.173M, consensus $119.35M. “Our third quarter results represent another period of significant CAPLYTA growth, and we are again increasing our revenue guidance for the full year 2023,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We continue to solidify CAPLYTA’s position as an important option in the treatment of bipolar depression and schizophrenia and we remain focused on advancing our pipeline, including additional lumateperone development programs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
- Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
- Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast
- Intra-Cellular Caplyta patent extension granted, says RBC Capital
- Intra-Cellular announces presentations at Psych Congress 2023